THROMBOREDUCTIN

Dose: 0.5 mg
Single Dose: 0.5 (0.5)
Frequency: 6 hourly
Route: PO
Instructions: This is the recomended starting dose. For one week. It is recommended that patients with moderate hepatic impairment start anagrelide therapy at a dose of 0.5 mg/day and be maintained for a minimum of one week with careful monitoring of cardiovascular effects. The dosage increment must not exceed more than 0.5 mg/day in any one-week. To monitor the effect of anagrelide and prevent the occurrence of thrombocytopenia, platelet counts should be performed every two days during the first week of treatment and at least weekly thereafter until the maintenance dosage is reached.

It belongs to Platelet-reducing agent. pharmacological group on the basis of mechanism of action. The Molecular Weight of Anagrelide is 255.00.

Anagrelide is contraindicated in conditions like Hypersensitivity.

The signs and symptoms that are produced after the acute overdosage of Anagrelide include Peripheral edema.The symptomatic adverse reactions produced by Anagrelide are more or less tolerable and if they become severe, they can be treated symptomatically, these include Flatulence, Dizziness, Headache, Nausea, Vomiting, Anorexia, Diarrhea, Fever, Dyspnea, Palpitation, Tachycardia, Abdominal pain, Rashes, Pruritus, Pain, Pharyngitis, Dyspepsia, Malaise, Cough, Asthenia, Edema, Chest pain, Paresthesias, Back pain.

Anagrelide is primarily indicated in conditions like Chronic myeloid leukaemia, Thrombocythaemia, and can also be given in adjunctive therapy as an alternative drug of choice in Myeloproliferative disorders, Thrombosis.

Anagrelide is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAspirinThe potential risks and benefits of concomitant use of anagrelide with aspirin should be assessed, particularly in patients with a high risk profile for haemorrhage, before treatment is commenced.Fluvoxamine (Maleate)Anagrelide is metabolized at least in part by CYP1A2. It is known that CYP1A2 is inhibited by several medicinal products, and such medicinal products could theoretically adversely influence the clearance of anagrelide.Milrinone (Lactate)It should not be diluted with NaCO3 injection. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

SGPT level disturbance. SGOT level disturbance

Drug should not be given to Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, and patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Caps Store Between 20°C-25°C. Protect from Sunlight.

Anagrelide should be used with caution in patients with known or suspected heart disease, and only if the potential benefits of therapy outweigh the potential risks. The potential risks and benefits of anagrelide therapy in a patient with mild and moderate impairment of hepatic function should be assessed before treatment is commenced. There are no special requirements for dosing the geriatric population.